Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC

Inclusion Criteria: * HCC with diagnosis confirmed pathologically or clinically * Patients who need to receive TACE and/or HAIC, or have plans to undergo another treatment (3-6 weeks after the previous treatment) * Child Pugh class A or B * ECOG PS 0-2 * PLT ≤ 75×10\^9/L (10 days before interventional therapy) Exclusion Criteria: * Thrombocytopenia caused by hematological diseases, non chemotherapy related thrombocytopenia (excluding liver cirrhosis with hypersplenism) * PLT \<30×10\^9/L * History of hepatic encephalopathy, refractory ascites, or hepatorenal syndrome * History of arterial or venous thrombosis within 6 months * Uncontrolled severe infections * Pregnant or breastfeeding female patients * Immune deficiencies, such as autoimmune diseases, HIV infected individuals, etc * Anticoagulation or antiplatelet therapy witch cannot be suspended during the treatment period: heparin, warfarin, rivaroxaban, dipyridamole, non-steroidal anti-inflammatory drugs, aspirin, verapamil, Ticlopidine, clopidogrel, glycoprotein IIb/IIIa antagonists, erythropoietin, etc; * Administration of blood products within 7 days prior to the baseline visit (excluding albumin infusion) * Allergy to avatrombopag or any of its formulations * History (such as gastrointestinal bleeding within 3 months, high risk of thrombosis, such as portal vein main flow velocity\<10cm/s) which may affect the safety of the patients or their ability to complete the study